Tag Archive for: Eli Lilly

A week after Britain’s debut of the four-week Kwikpen, a European Medicines Agency panel is slated to review Eli Lilly’s multi-dose, pre-filled pen injector for diabetes drug Mounjaro.

Eli Lilly’s Mounjaro is being launched in Britain this week, two pharmacy companies said on Wednesday, making the UK the fourth European country to introduce the highly anticipated obesity drug.

Two Florida courts last week ruled in Novo Nordisk’s favor in its legal battle against wellness clinics and compounding pharmacies for marketing counterfeit or compounded versions of its popular weight-loss drug semaglutide.

The European Medicines Agency is investigating the potential impacts that Novo Holdings’ $16.5 billion acquisition of contract manufacturing giant Catalent will have on drug supply, according to reporting Wednesday by Reuters.

Eli Lilly agreed to provide low-cost insulin to patients and donate free insulin to clinics, to settle a lawsuit by Minnesota that accused the three largest insulin makers of deceptively raising the price of the diabetes treatment.

The company said it is already making manufacturing investments for orforglipron, its next-generation oral weight-loss candidate that recently moved into Phase III development.

U.S. inspectors recently uncovered new manufacturing problems at an Eli Lilly (LLY.N) plant that has been under scrutiny by federal investigators, according to government records obtained by Reuters.

Eli Lilly’s Jaypirca (pirtobrutinib) is forecast to become the market leader in BTK inhibitors for CLL, garnering nearly 60% share with about $3 billion in sales by 2032, according to GlobalData.

As JPM week drew to a close, Lilly CEO David Ricks discussed what he sees in store for the biopharma industry.

The strategic acquisition provides Roche access to Carmot’s portfolio, which notably includes three lead molecules, all GLP-1 analogues, currently in the advanced stages of clinical trials for obesity and type 2 diabetes. It also positions the company on par with other industry leaders in the realm of GLP-1 analogues, such as Novo Nordisk, Eli Lilly and others.